In patient trials, effective CTL responses to a tumour antigen were generated following vaccination and anti-CD25 Treg depletion in patients with metastatic cancers [61], [62] and improved survival resulted from inclusion of anti-CTLA-4 treatment with immunization for metastatic melanoma [63]. The gene discussed is CTLA4; the disease is metastatic melanoma.